Perrigo Inks $2.85B Divestiture Amid Activist Pressure

Perrigo, amid pressure from activist hedge fund Starboard, said it will sell the royalty rights for a blockbuster multiple sclerosis drug to Royalty Pharma in a Monday deal that could be...

Already a subscriber? Click here to view full article